D. Boral Capital Reaffirms “Buy” Rating for Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ:ENLV)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Separately, HC Wainwright increased their price objective on Enlivex Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, March 24th.

Enlivex Therapeutics Stock Performance

ENLV stock opened at $0.89 on Thursday. Enlivex Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.21. The stock has a market capitalization of $19.01 million, a price-to-earnings ratio of -0.91 and a beta of 0.85. The stock’s fifty day moving average is $1.07 and its two-hundred day moving average is $1.22.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.07). As a group, analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Enlivex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Securities LLC bought a new position in Enlivex Therapeutics during the fourth quarter valued at about $26,000. Renaissance Technologies LLC grew its holdings in shares of Enlivex Therapeutics by 112.6% in the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after acquiring an additional 84,203 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Enlivex Therapeutics during the fourth quarter worth $742,000. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.